Hepatology International

Article	Citations
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease	399
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)	189
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?	140
Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis	99
Liver injury in remdesivir-treated COVID-19 patients	91
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study	91
Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis	85
Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis	82
Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases	65
The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040	65
Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI)	62
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines	59
Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations	59
Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma	58
Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders	57
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy	56
Liver injury in patients with COVID-19: clinical profiles, CT findings, the correlation of the severity with liver injury	56
Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial	51
Current perspectives on the tumor microenvironment in hepatocellular carcinoma	47
Effect of COVID-19 on patients with compensated chronic liver diseases	47
Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation	46
APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients	42
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?	42
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	41
Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial	40

Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients	40
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort	38
Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL)	38
Intestinal failure-associated liver disease (IFALD): insights into pathogenesis and advances in management	38
A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC	38
The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis	37
Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis	37
Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group	36
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial	34
The role of neutrophils in innate immunity-driven nonalcoholic steatohepatitis: lessons learned and future promise	34
SARS-CoV-2 infection and liver involvement	33
Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China	33
Cell cycle regulation in NAFLD: when imbalanced metabolism limits cell division	33
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study	33
High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B	33
Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism	32
Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study	30
The global trends and regional differences in incidence and mortality of hepatitis A from 1990 to 2019 and implications for its prevention	30
Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study	29
An international multidisciplinary consensus statement on MAFLD and the risk of CVD	28
Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis	28
Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease	28
A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes	28
Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease	27
Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC	27
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis	26
Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial	26
Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population	26
Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)	25
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis	25
Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure	24
Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection	24
Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer	24
Management of primary sclerosing cholangitis and its complications: an algorithmic approach	23
Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study	23
Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice	22
Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study	22
Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis	22
Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China	22
Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China	22
First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients	22
Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI	22
Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy	21
Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease	21
Chronic hepatitis B: the demise of the ‘inactive carrier’ phase	21
APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19	21
Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation	21
The metabolic profiles and body composition of lean metabolic associated fatty liver disease	20
Interleukin-22 in alcoholic hepatitis and beyond	20
Abstract	20

Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan	20
Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load	19
A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population	19
Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis	18
Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study	18
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B	18
Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer	18
Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial	17
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population	17
Management of hepatitis B virus reactivation due to treatment of COVID-19	17
Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation	17
Radiomics analysis of contrast-enhanced CT for staging liver fibrosis: an update for image biomarker	17
Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study	17
Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis	17
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B	17
Silencing of functional p53 attenuates NAFLD by promoting HMGB1-related autophagy induction	16
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients	16
CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection	16
Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study	16
The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study	16
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment	16
Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study	16
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies	16
Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease	16
Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib	15
Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice	15
Increased risk of cancer in patients with primary sclerosing cholangitis	15
Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines	15
Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications	15
Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study	15
Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure	15
A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion	15
Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis	15
Implications of liver injury in risk-stratification and management of patients with COVID-19	15
Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy	15
Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients	15
A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis	15
Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study	15
Longitudinal progression of clinical variables associated with graded liver injury in COVID-19 patients	15
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan	14
Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial	14
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients	14
Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis	14
Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease	14
Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia	14
A prognostic model of acute-on-chronic liver failure based on sarcopenia	14
Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease	14
The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes	13
Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis	13
Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease	13
Novel systemic therapy for hepatocellular carcinoma	12
Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies	12
Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma	12
Regression of portal hypertension: underlying mechanisms and therapeutic strategies	12
Identification of blood metabolites linked to the risk of cholelithiasis: a comprehensive Mendelian randomization study	12
Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF	12
Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait	12
S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma	12
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients	12
Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil	12
Application of CRISPR-Cas9 based gene editing to study the pathogenesis of colon and liver cancer using organoids	11
Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice	11
Dynamic analysis of serum MMP-7 and its relationship with disease progression in biliary atresia: a multicenter prospective study	11
Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt	11
Models for acute on chronic liver failure development and mortality in a veterans affairs cohort	11
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma	11
Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation	11
Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn’s disease but not Ulcerative Colitis: a prospective cohort study	11
Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study	11
Primary prophylaxis of gastric variceal bleeding: endoscopic obturation, radiologic intervention, or observation?	11
Deep learning for evaluation of microvascular invasion in hepatocellular carcinoma from tumor areas of histology images	11
A novel machine learning-based radiomic model for diagnosing high bleeding risk esophageal varices in cirrhotic patients	11
Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis	11
Portal vein thrombosis associated with high 14-day and 6-week rebleeding in patients after oesophageal variceal band ligation: a retrospective, multicentre, nested case–control study	11
Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank	10
A novel, bedside, etiology specific prognostic model (Peds-HAV) in hepatitis A induced pediatric acute liver failure	10
Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B	10
Maternal–fetal outcome in pregnancies complicated with non-cirrhotic portal hypertension: experience from a Tertiary Centre in South India	10
Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy	10
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma	10

Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study	10
Low platelets: a new and simple prognostic marker for patients with hepatitis E virus-related acute liver failure	10
Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study	10
Association between metabolically healthy obesity and non-alcoholic fatty liver disease	10
A novel epithelial–mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma	10
"Fast, faster, and fastest: science on the run during COVID-19 drama"—"do not forget the liver"	10
Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding	9
Establishment of a murine model of acute-on-chronic liver failure with multi-organ dysfunction	9
Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation	9
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	9
Consensus on the secondary prevention of primary liver cancer	9
Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients	9
Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome	9
Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial	9
Plasma perfusion combined with plasma exchange in chronic hepatitis B-related acute-on-chronic liver failure patients	9
Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants	9
Association of arterial stiffness with the histological severity of nonalcoholic fatty liver disease	9
Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury	9
Viscoelastic test-based bleeding risk score reliably predicts coagulopathic bleeding in decompensated cirrhosis and ACLF patients	9
Dynamic Optic Nerve Sheath Diameter (ONSD) guided management of raised intracranial pressure in pediatric acute liver failure	9
Double-blind placebo-controlled randomized trial of N-acetylcysteine infusion following live donor liver transplantation	9
Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension	9
miR-98-5p as a novel biomarker suppress liver fibrosis by targeting TGFβ receptor 1	9
Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma	9
Countdown on hepatitis B elimination by 2030: the global burden of liver disease related to hepatitis B and association with socioeconomic status	9
‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure	9
Influence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	8
Portal inflammation predicts renal dysfunction in patients with nonalcoholic fatty liver disease	8
Propranolol vs. band ligation for primary prophylaxis of variceal hemorrhage in cirrhotic patients with ascites: a randomized controlled trial	8
Impact of propofol sedation on the diagnostic accuracy of hepatic venous pressure gradient measurements in patients with cirrhosis	8
COVID-19 in decompensated cirrhosis	8
Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma	8
Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages 0–A hepatocellular carcinoma patients associated with or without microvascular invasion: a	8
Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC)	8
Accuracy of contrast-enhanced ultrasound liver imaging reporting and data system: a systematic review and meta-analysis	8
Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data	8
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort	8
Proposed mechanism for increased COVID-19 mortality in patients with decompensated cirrhosis	8
The overview of the deep learning integrated into the medical imaging of liver: a review	8
Chronic liver disease independently associated with COVID-19 severity: evidence based on adjusted effect estimates	8
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort	8
Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial	8
Application of machine learning in liver transplantation: a review	8
Associations between intake of starchy and non-starchy vegetables and risk of hepatic steatosis and fibrosis	8
Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B	8
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study	8
Liver transplantation in patients with acute-on-chronic liver failure	7
The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma	7
Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial	7
Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke	7
Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection	7
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5	7
Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study	7
Hepatopulmonary syndrome is related to the development of acute-on-chronic liver failure and poor prognosis in cirrhotic patients	7
Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials	7
Chronic intermittent hypoxia contributes to non-alcoholic steatohepatitis progression in patients with obesity	7
Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm	7
A community of portal hypertension	7
Artificial intelligence CT radiomics to predict early recurrence of intrahepatic cholangiocarcinoma: a multicenter study	7
Distribution and clinical relevance of phospholipids in hepatocellular carcinoma	7
Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma	7
Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study	7
Multiple cycles of granulocyte colony-stimulating factor in decompensated cirrhosis: a double-blind RCT	7
Diabetes is associated with poor short-term prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure	7
Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease	7
Acute liver failure in Budd–Chiari syndrome and a model to predict mortality	7
MAFLD: perceived stigma—a single-center Mexican patient survey	7
Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review	7
A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat?	7
HMGCL-induced β-hydroxybutyrate production attenuates hepatocellular carcinoma via DPP4-mediated ferroptosis susceptibility	7
Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion	7
Efficacy of apatinib in patients with sorafenib–transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study	6
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan	6
A novel radiomics–platelet nomogram for the prediction of gastroesophageal varices needing treatment in cirrhotic patients	6
One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment	6
Asia–Pacific association for study of liver guidelines on management of ascites in liver disease	6
Aspirin improves transplant-free survival after TIPS implantation in patients with refractory ascites: a retrospective multicentre cohort study	6
Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial	6
Weight fluctuation and risk of hepatocellular carcinoma: a nationwide population-based 8-million-subject study	6
The characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patients	6
Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	6
Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response	6
Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease	6
Contribution of alcohol use to the global burden of cirrhosis and liver cancer from 1990 to 2019 and projections to 2044	6
Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies	6
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	6
Hepatic fibrosis is associated with an increased rate of decline in bone mineral density in men with nonalcoholic fatty liver disease	6
Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure	6
GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial	6
Image-matching digital macro-slide—a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma	6
Neonatal hepatitis B vaccination protects mature adults from occult virus infection	6
Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?	6
Assessment of liver fibrosis by transient elastography in young children with chronic hepatitis B virus infection	6
Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma	6
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	6